Scientific Reports
November 10, 2023
Lucas Cruz, Bheatrix Bienemann, Fernanda Palhano-Fontes et al.
3 citations
Ayahuasca is a brew with psychoactive properties that has been used as an entheogen for centuries, with more recent studies suggesting it is a promising treatment for some clinical disorders. Although there is an emerging scientific literature on its effects, to the best of our knowledge no study has explored the self-reported experiences of first-time ayahuasca users with quantitative textual...
Journal of Affective Disorders
November 8, 2023
Itsuki Terao, Takahiro Tsuge, Kaori Endo et al.
32 citations
BACKGROUND Intravenous racemic ketamine is a promising treatment for treatment-resistant depression. However, its clinical utility compared with intranasal esketamine and the other well-studied conventional pharmacological interventions (i.e., aripiprazole and lithium) as augmentative treatments for treatment-resistant unipolar depression in adults remains unclear. Therefore, we aimed to...
Pharmaceuticals
November 7, 2023
Courtney M Vecera, Alan C. Courtes, Gregory Jones et al.
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the...
Quality of Life Research
November 2023
Carol Jamieson, Carla M. Canuso, Dawn F. Ionescu et al.
To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18-64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the...
Journal of Trauma Nursing
November 1, 2023
Caitlyn B. Coffelt, Kyle Gibson, Jason VanLandingham
BACKGROUND: This case report describes the use of ketamine as a rapid, effective treatment of depression in a 68-year-old female patient with no significant medical history of psychiatric disorders. Patients who experience intentional or unintentional traumas are at an increased risk for developing depression or posttraumatic stress disorder, and emerging evidence has supported the use of...
Cureus
November 1, 2023
Maninder Sohi, Lakshit Jain, Michael Ang-Rabanes et al.
Major depressive disorder (MDD) is associated with both insomnia and hypersomnia, but it predominantly decreases sleep continuity and leads to a decrease in rapid eye movement (REM) latency, an increase in REM sleep duration, and an increase in REM density. Some of these changes persist even when MDD is treated and can be associated with a recurrence of MDD. Antidepressants can potentially...
Journal of Psychiatric Research
November 1, 2023
Hui Kou, Wei Luo, Xinnan Liu et al.
11 citations
Mindfulness training has been shown to improve emotional symptoms such as anxiety and depressive symptoms. However, its cognitive-behavioral mechanism is still unclear. The present study aimed to investigate the effect of mindfulness training on attention to emotional faces and its role in the improvement in emotional symptoms. Eighty participants were recruited and randomly divided into a...
Journal of Nursing Scholarship
November 1, 2023
Susan Musto, April Hazard Vallerand
21 citations
The purpose of this paper was to review and synthesize published research articles that have utilized yoga nidra as an intervention. Yoga nidra is a form of guided meditation that has emerged in the literature in the past two decades as an intervention for a variety of medical conditions such as stress and mental health. It differs from traditional yoga, in that it does not require yoga poses....
Neuropsychopharmacology
November 1, 2023
Nicolas Garel, Kyle T. Greenway, Lê-Anh Dinh-Williams et al.
10 citations
We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none...
Molecular Psychiatry
November 1, 2023
L. Taylor Flynn, Wen-Jun Gao
14 citations
Psychedelic compounds are being increasingly explored as a potential therapeutic option for treating several psychiatric conditions, despite relatively little being known about their mechanism of action. One such possible mechanism, DNA methylation, is a process of epigenetic regulation that changes gene expression via chemical modification of nitrogenous bases. DNA methylation has been...
Psychiatry Research
November 1, 2023
Sipan Haikazian, David C J Chen-Li, Danica E. Johnson et al.
121 citations
The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome...
Frontiers in Psychiatry
October 31, 2023
Albino J Oliveira-Maia, Benoit Rive, Joachim Morrens et al.
6 citations
BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI). How esketamine NS compares with commonly used real-world (RW) polypharmacy...
The Brown University Psychopharmacology Update
October 30, 2023
A single 25‐mg dose of psilocybin administered with psychological support led to significant and sustained improvement in depressive symptoms compared with placebo in a Phase 2 study of patients with major depressive disorder. A higher number of adverse events occurred in the psilocybin group, but no serious treatment‐emergent adverse events were reported. Study results were published online...
Frontiers in Neuroscience
October 26, 2023
Weronika Dębowska, Magdalena Więdłocha, Marta Dębowska et al.
Drug-resistant mental disorders, particularly treatment-resistant depression, pose a significant medical and social problem. To address this challenge, modern psychiatry is constantly exploring the use of novel treatment methods, including biological treatments, such as transcranial magnetic stimulation (TMS), and novel rapid-acting antidepressants, such as ketamine. While both TMS and ketamine...
iScience
October 20, 2023
Jie-Ying Chen, Ke Wu, Miao-Miao Guo et al.
Depression is a global disease with a high prevalence. Here, we examine the role of the circuit from prelimbic mPFC (PrL) to the anterior ventral bed nucleus of the stria terminalis (avBNST) in depression-like mice through behavioral tests, immunofluorescence, chemogenetics, optogenetics, pharmacology, and fiber photometry. Mice exposed to chronic restraint stress with individual housing...
Nature Mental Health
October 19, 2023
Theresa R. Lii, Ashleigh E. Smith, Josephine R. Flohr et al.
94 citations
Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials. Here we present a single-center, parallel-arm, triple-masked, randomized, placebo-controlled trial assessing the antidepressant efficacy of intravenous ketamine masked by surgical anesthesia (ClinicalTrials.gov, NCT03861988). Adult patients (N = 40) with...
Evidence-Based Practice
October 19, 2023
Lucia Carbajal, Tessa E. Moore, R. H. Barry Sample et al.
Carbajal, Lucia MD; Moore, Tessa MD; Sample, Reise MD; Nelson, Joseph MD Author Information
Psychiatry Research Case Reports
October 18, 2023
Giacomo D’andrea, Ornella di Marco, Francesco Maria Semeraro et al.
1 citation
Rapid Cyclic Bipolar Disorder (RCBD) is a debilitating condition that manifests as four or more episodes of depression, mania, or hypomania in a span of one year, with depression being the predominant event. RCBD is prevalent among individuals diagnosed with bipolar disorder and is associated with elevated suicide risk, prolonged disease duration, unfavorable clinical outcomes, and cognitive...
BMC Psychiatry
October 17, 2023
Paul A Bloom, David Pagliaccio, Jiahe Zhang et al.
17 citations
Adolescence is characterized by a heightened vulnerability for Major Depressive Disorder (MDD) onset, and currently, treatments are only effective for roughly half of adolescents with MDD. Accordingly, novel interventions are urgently needed. This study aims to establish mindfulness-based real-time fMRI neurofeedback (mbNF) as a non-invasive approach to downregulate the default mode network...
Clinical Psychopharmacology and Neuroscience
October 16, 2023
Tessa Watford, Naqash Masood
21 citations
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive...